Compare WBX & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WBX | CRDL |
|---|---|---|
| Founded | 2015 | 2017 |
| Country | Spain | Canada |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 118.0M | 97.3M |
| IPO Year | N/A | N/A |
| Metric | WBX | CRDL |
|---|---|---|
| Price | $2.37 | $0.99 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | $9.00 | $9.00 |
| AVG Volume (30 Days) | 33.3K | ★ 445.0K |
| Earning Date | 02-26-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $174,593,453.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $37.11 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.30 | $0.77 |
| 52 Week High | $14.40 | $1.59 |
| Indicator | WBX | CRDL |
|---|---|---|
| Relative Strength Index (RSI) | 25.90 | 46.12 |
| Support Level | $2.30 | $0.94 |
| Resistance Level | $3.36 | $1.03 |
| Average True Range (ATR) | 0.20 | 0.04 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 6.60 | 26.06 |
Wallbox NV is a smart electric vehicle charging and energy management company. It creates a smart charging system combining technology design that manages the communication between the user, vehicle, grid, building, and charger. The company designs, manufactures, and distributes faster, simpler EV charging solutions for residential, business, and public use. Its smart charging product portfolio includes Level 2 alternating current chargers for home and business applications and direct current fast chargers for public applications. The company has three reportable operating segments; Europe, Middle East and Asia (EMEA), its key revenue-generating segment, North America, and Asia-Pacific.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.